BP
ABUS icon

Ballentine Partners’s Arbutus Biopharma ABUS Stock Holding History

Ballentine Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,121
Closed -$102K – 913
2024
Q4 		$102K Buy
+31,121
New +$114K ﹤0.01% 843

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Ballentine Partners's ABUS Position: Q1 2025 in Review

Ballentine Partners sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 31,121 shares — an estimated $102K sold.

Ballentine Partners first reported a position in ABUS in Q4 2024 and held it in 1 quarter. The position peaked at $102K in Q4 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • Ballentine Partners reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • Ballentine Partners sold 31,121 Arbutus Biopharma shares in Q1 2025, an estimated $102K.
  • Ballentine Partners first reported a position in Arbutus Biopharma in Q4 2024 and held it in 1 quarter.
  • Ballentine Partners's Arbutus Biopharma position peaked at $102K in Q4 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on Ballentine Partners's 13F filing for Q1 2025, filed 1 May 2025.